Skip to content
Catalyst

sertralineWhat was measured

Measured, with no finding

924 endpoints

Show what was measuredHide what was measured
  • abdominal pain

    increases, p = 0.03, n = 55

    abdominal pain than imipramine (OR 4.13, 95% CI 1.12 to 15.25, P = 0.03; 1 trial, 55 participants)

    PMID 20393946 · one of two readings recorded this

  • agitation/anxiety

    increases, p = 0.02, n = 160

    nefazodone (OR 4.71, 95% CI 1.29 to 17.24, P = 0.02; 1 trial, 160 participants)

    PMID 20393946 · one of two readings recorded this

  • anorgasmia

    decreases, p = 0.03, n = 353

    anorgasmia (OR 0.19, 95% CI 0.04 to 0.89, p = 0.03; 1 trial, 353 participants

    PMID 20393946 · one of two readings recorded this

  • appetite increase

    decreases, p = 0.007, n = 263

    appetite increase than amitriptyline (OR 0.06, 95% CI 0.01 to 0.45, P = 0.007; 1 trial, 263 participants

    PMID 20393946 · one of two readings recorded this

  • appetite increase

    decreases, p = 0.0002, n = 596

    appetite increase (OR 0.20, 95% CI 0.09 to 0.46, p = 0.0002; 2 trials, 596 participants

    PMID 20393946 · one of two readings recorded this

  • appetite loss/anorexia

    increases, p = 0.009, n = 539

    appetite loss/anorexia (OR 7.14, 95% CI 1.63 to 31.18, P = 0.009; 2 trials, 539 participants

    PMID 20393946 · one of two readings recorded this

  • constipation

    decreases, p = 0.00001, n = 1158

    amitriptyline (OR 0.37, 95% CI 0.25 to 0.55, P<0.00001; 6 trials, 1158 participants)

    PMID 20393946 · one of two readings recorded this

  • constipation

    decreases, p = 0.0008, n = 304

    clomipramine (OR 0.18, 95% CI 0.07 to 0.49, P = 0.0008; 3 trials, 304 participants)

    PMID 20393946 · one of two readings recorded this

  • constipation

    decreases, p = 0.03, n = 487

    imipramine (OR 0.17, 95% CI 0.03 to 0.87, P = 0.03; 4 trials, 487 participants)

    PMID 20393946 · one of two readings recorded this

  • constipation

    decreases, p = 0.0002, n = 210

    nortriptyline (OR 0.28, 95% CI 0.14 to 0.54, P = 0.0002; 1 trial, 210 participants)

    PMID 20393946 · one of two readings recorded this

  • constipation

    decreases, p = 0.0002, n = 545

    paroxetine (OR 0.31, 95% CI 0.16 to 0.58, P = 0.0002; 2 trials, 545 participants)

    PMID 20393946 · one of two readings recorded this

  • constipation

    decreases, p = 0.04, n = 89

    venlafaxine (OR 0.05, 95% CI 0.00 to 0.85, P = 0.04; 1 trial, 89 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.0005, n = 779

    amitriptyline (OR 11.32, 95% CI 2.90 to 44.18, P = 0.0005; 3 trials, 779 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.005, n = 727

    bupropion (OR 3.88, 95% CI 1.50 to 10.07, P = 0.005; 3 trials, 727 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.02, n = 198

    clomipramine (OR 4.30, 95% CI 1.28 to 14.44, P = 0.02; 2 trials, 198 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.007, n = 489

    escitalopram (OR 2.10, 95% CI 1.22 to 3.61, P = 0.007; 2 trials, 489 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.001, n = 314

    hypericum (OR 2.30, 95% CI 1.39 to 3.80, P = 0.001; 2 trials, 314 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.004, n = 398

    imipramine (OR 6.75, 95% CI 1.82 to 24.97, P = 0.004; 3 trials, 398 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.0009, n = 596

    mirtazapine (OR 2.74, 95% CI 1.52 to 4.97, P = 0.0009; 2 trials, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.04, n = 210

    nortriptyline (OR 2.17, 95% CI 1.02 to 4.64, P = 0.04; 1 trial, 210 participants)

    PMID 20393946 · one of two readings recorded this

  • diarrhoea

    increases, p = 0.0001, n = 545

    paroxetine (OR 2.51, 95% CI 1.66 to 3.80, P<0.0001; 2 trials, 545 participants)

    PMID 20393946 · one of two readings recorded this

  • dizziness

    decreases, p = 0.01, n = 1158

    dizziness than amitriptyline (OR 0.61, 95% CI 0.42 to 0.89, P = 0.01; 6 trials, 1158 participants)

    PMID 20393946 · one of two readings recorded this

  • dizziness

    decreases, p = 0.006, n = 398

    imipramine (OR 0.46, 95% CI 0.26 to 0.80, P = 0.006; 3 trials, 398 participants)

    PMID 20393946 · one of two readings recorded this

  • dizziness

    decreases, p = 0.0003, n = 160

    dizziness (OR 0.17, 95% CI 0.06 to 0.44, p = 0.0003; 1 trial, 160 participants

    PMID 20393946 · one of two readings recorded this

  • dropout due to any cause

    increases, p = 0.04, n = 727

    bupro-pion for discontinuation due to any cause (OR 1.42, 95% CI 1.02 to 1.99, p = 0.04; 3 studies, 727 participants)

    PMID 20393946 · one of two readings recorded this

  • dropout due to any cause

    decreases, p = 0.03, n = 641

    fewer patients allocated to sertraline withdrawing from studies than those allocated to imipramine for discontinuation due to any cause (OR 0.62, 95% CI 0.40 to 0.96, p = 0.03; 5 studies, 641 participants)

    PMID 20393946 · one of two readings recorded this

  • dropout due to any cause

    decreases, p = 0.05, n = 596

    mirtazapine for discontinuation due to any cause (OR 0.68, 95% CI 0.47 to 0.99, p = 0.05; 2 studies, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • dropout due to side effects

    no effect, p = 0.06, n = 1457

    the difference between sertraline and amitriptyline was in favour of sertraline (OR 0.74, 95% CI 0.55 to 1.01, P = 0.06; 7 studies, 1457 participants)

    PMID 20393946 · one of two readings recorded this

  • dropout due to side effects

    decreases, p = 0.06, n = 596

    mirtazapine (OR 0.35, 95% CI 0.17 to 0.74, p = 0.06; 2 studies, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • dropout due to side effects

    decreases, p = 0.04, n = 311

    fewer patients allocated to sertraline withdrew from study than paroxetine for discontinuation due to side effects (OR 0.28, 95% CI 0.08 to 0.96, p = 0.04; 3 studies, 311 participants)

    PMID 20393946 · one of two readings recorded this

  • dropout due to side effects

    decreases, p = 0.001, n = 611

    venlafaxine (OR 0.33, 95% CI 0.17 to 0.64, p = 0.001; 5 studies, 611 participants)

    PMID 20393946 · one of two readings recorded this

  • dry mouth

    decreases, p = 0.00001, n = 1158

    amitriptyline (OR 0.16, 95% CI 0.11 to 0.24, P<0.00001; 6 trials, 1158 participants)

    PMID 20393946 · one of two readings recorded this

  • dry mouth

    decreases, p = 0.01, n = 304

    clomipramine (OR 0.30, 95% CI 0.12 to 0.78, P = 0.01; 3 trials, 304 participants)

    PMID 20393946 · one of two readings recorded this

  • dry mouth

    decreases, p = 0.0001, n = 487

    imipramine (OR 0.16, 95% CI 0.06 to 0.40, P = 0.0001; 4 trials, 487 participants)

    PMID 20393946 · one of two readings recorded this

  • dry mouth

    no effect, p = 0.05, n = 64

    this difference was in favour of sertraline (OR 0.20, 95% CI 0.04 to 1.03, P = 0.05; 1 study, 64 participants)

    PMID 20393946 · one of two readings recorded this

  • dry mouth

    decreases, p = 0.00001, n = 210

    nortriptyline (OR 0.22, 95% CI 0.12 to 0.39, P<0.00001; 1 trial, 210 participants)

    PMID 20393946 · one of two readings recorded this

  • dry mouth

    decreases, p = 0.003, n = 49

    reboxetine (OR 0.04, 95% CI 0.00 to 0.34, P = 0.003; 1 trial, 49 participants)

    PMID 20393946 · one of two readings recorded this

  • dry mouth

    decreases, p = 0.006, n = 89

    venlafaxine (OR 0.02, 95% CI 0.00 to 0.33, P = 0.006; 1 trial, 89 participants)

    PMID 20393946 · one of two readings recorded this

  • ejaculation disorder

    decreases, p = 0.0009, n = 545

    ejaculation disorder (OR 0.29, 95% CI 0.14 to 0.60, p = 0.0009; 2 trials, 545 participants

    PMID 20393946 · one of two readings recorded this

  • fatigue

    decreases, p = 0.004, n = 596

    fatigue (OR 0.44, 95% CI 0.25 to 0.77, p = 0.004; 2 trials, 596 participants

    PMID 20393946 · one of two readings recorded this

  • gastrointestinal symptoms or dyspepsia

    increases, p = 0.003, n = 250

    gastrointestinal symptoms or dyspepsia (OR 3.54, 95% CI 1.52 to 8.23, p = 0.003; 1 trial, 250 participants

    PMID 20393946 · one of two readings recorded this

  • gastrointestinal symptoms

    decreases, p = 0.005, n = 77

    desipramine (OR 0.24, 95% CI 0.09 to 0.65, P = 0.005; 1 trial, 77 participants

    PMID 20393946 · one of two readings recorded this

  • headache

    increases, p = 0.04, n = 1090

    headache (OR 1.60, 95% CI 1.03 to 2.48, P = 0.04; 5 trials, 1090 participants

    PMID 20393946 · one of two readings recorded this

  • headache

    increases, p = 0.04, n = 596

    headache (OR 1.53, 95% CI 1.01 to 2.30, p = 0.04; 2 trials, 596 participants

    PMID 20393946 · one of two readings recorded this

  • increased sweating

    increases, p = 0.002, n = 727

    increased sweating (OR 3.99, 95% CI 1.68 to 9.45, p = 0.002; 2 trials, 727 participants

    PMID 20393946 · one of two readings recorded this

  • increased sweating

    increases, p = 0.01, n = 314

    increased sweating (OR 1.97, 95% CI 1.15 to 3.38, p = 0.01; 2 trials, 314 participants

    PMID 20393946 · one of two readings recorded this

  • increased sweating

    increases, p = 0.04, n = 259

    increased sweating (OR 2.44, 95% CI 1.05 to 5.67, p = 0.04; 2 trials, 259 participants

    PMID 20393946 · one of two readings recorded this

  • increased sweating

    decreases, p = 0.05, n = 49

    increased sweating (OR 0.05, 95% CI 0.00 to 0.94, p = 0.05; 1 trial, 49 participants

    PMID 20393946 · one of two readings recorded this

  • insomnia

    increases, p = 0.002, n = 802

    higher rate of participants experiencing insomnia than amitriptyline (OR 2.29, 95% CI 1.37 to 3.83, P = 0.002; 3 trials, 802 participants)

    PMID 20393946 · one of two readings recorded this

  • insomnia

    increases, p = 0.02, n = 596

    insomnia than mirtazapine (OR 2.72, 95% CI 1.15 to 6.43, P = 0.02; 2 trials, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • libido decrease

    increases, p = 0.03, n = 346

    libido decrease (OR 5.44, 95% CI 1.17 to 25.19, p = 0.03; 1 trial, 346 participants

    PMID 20393946 · one of two readings recorded this

  • mean change in depressive symptoms

    decreases, p = 0.009, n = 1172

    Sertraline was found to be less efficacious than amitriptyline in reduction of depressive symptoms (SMD 0.18, 95% CI 0.04 to 0.32, p = 0.009; 7 studies, 1172 participants)

    PMID 20393946 · one of two readings recorded this

  • nausea

    increases, p = 0.00001, n = 1090

    amitriptyline (OR 4.90, 95% CI 3.09 to 7.76, P<0.00001; 5 trials, 1090 participants)

    PMID 20393946 · one of two readings recorded this

  • nausea

    increases, p = 0.02, n = 727

    bupropion (OR 2.14, 95% CI 1.12 to 4.08, P = 0.02; 3 trials, 727 participants)

    PMID 20393946 · one of two readings recorded this

  • nausea

    increases, p = 0.003, n = 314

    hypericum (OR 3.43, 95% CI 1.52 to 7.76, P = 0.003; 2 trials, 314 participants)

    PMID 20393946 · one of two readings recorded this

  • nausea

    increases, p = 0.01, n = 487

    imipramine (OR 2.68, 95% CI 1.26 to 5.73, P = 0.01 4 trials, 487 participants)

    PMID 20393946 · one of two readings recorded this

  • nausea

    increases, p = 0.00001, n = 596

    mirtazapine (OR 3.68, 95% CI 2.10 to 6.45, P<0.00001; 2 trials, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • nausea

    increases, p = 0.02, n = 210

    nortriptyline (OR 2.42, 95% CI 1.14 to 5.13, P = 0.02; 1 trial, 210 participants)

    PMID 20393946 · one of two readings recorded this

  • neurological problems (peripheral and central nervous system)

    decreases, p = 0.04, n = 309

    amitriptyline (OR 0.31, 95% CI 0.10 to 0.95, P = 0.04; 2 trials, 309 participants)

    PMID 20393946 · one of two readings recorded this

  • neurological problems (peripheral and central nervous system)

    decreases, p = 0.01, n = 40

    clomipramine (OR 0.11, 95% CI 0.02 to 0.61, P = 0.01; 1 trial, 40 participants)

    PMID 20393946 · one of two readings recorded this

  • oftalmological problems

    increases, p = 0.05, n = 62

    oftalmological problems (OR 8.96, 95% CI 1.05 to 76.74, p = 0.05; 1 trial, 62 participants

    PMID 20393946 · one of two readings recorded this

  • pain

    decreases, p = 0.05, n = 241

    pain (OR 0.19, 95% CI 0.04 to 0.09, P = 0.05; 1 trial, 241 participants)

    PMID 20393946 · one of two readings recorded this

  • patients experiencing at least one side effect

    decreases, p = 0.01, n = 999

    Patients allocated to sertraline had a fewer rate of adverse events than amitriptyline (OR 0.59, 95% CI 0.39 to 0.89, p = 0.01; 5 studies, 999 participants)

    PMID 20393946 · one of two readings recorded this

  • patients experiencing at least one side effect

    increases, p = 0.03, n = 489

    higher rate of adverse events than escitalopram (OR 1.76, 95% CI 1.06 to 2.94, p = 0.03; 2 studies, 489 participants)

    PMID 20393946 · one of two readings recorded this

  • patients experiencing at least one side effect

    decreases, p = 0.00001, n = 209

    imipramine (OR 0.17, 95% CI 0.09 to 0.32, P<0.00001; 2 studies, 209 participants)

    PMID 20393946 · one of two readings recorded this

  • remission

    increases, p = 0.05, n = 482

    There was evidence that sertraline was more effective than imipramine (OR 0.67, 95% CI 0.45 to 0.99, p = 0.05; 3 studies, 482 participants)

    PMID 20393946 · one of two readings recorded this

  • remission

    decreases, p = 0.008, n = 596

    sertraline was less effective than mirtazapine (OR 1.92, 95% CI 1.18 to 3.13, p = 0.008; 2 studies, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • sexual problems

    increases, p = 0.0005, n = 259

    sexual problems (OR 3.56, 95% CI 1.74 to 7.30, P = 0.0005; 2 trials, 259 participants

    PMID 20393946 · one of two readings recorded this

  • sexual problems

    increases, p = 0.02, n = 90

    sexual problems (OR 4.00, 95% CI 1.31 to 12.23, p = 0.02; 1 trial, 90 participants

    PMID 20393946 · one of two readings recorded this

  • sleepiness/drowsiness

    decreases, p = 0.00001, n = 1090

    lower rate of participants experiencing sleepiness than amitriptyline (OR 0.27, 95% CI 0.19 to 0.40, P<0.00001; 5 trials, 1090 participants)

    PMID 20393946 · one of two readings recorded this

  • sleepiness/drowsiness

    increases, p = 0.00001, n = 727

    bupropion (OR 5.10, 95% CI 2.53 to 10.31, P<0.00001; 3 trials, 727 participants)

    PMID 20393946 · one of two readings recorded this

  • sleepiness/drowsiness

    decreases, p = 0.00001, n = 596

    mirtazapine (OR 0.33, 95% CI 0.20 to 0.54, P<0.00001; 2 trials, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • sweating increase

    increases, p = 0.05, n = 346

    sweating increase (OR 4.86, 95% CI 1.04 to 22.85, p = 0.05; 1 trial, 346 participants

    PMID 20393946 · one of two readings recorded this

  • sweating increase

    increases, p = 0.04, n = 160

    sweating increase (OR 3.01, 95% CI 1.03 to 8.79, p = 0.04; 1 trial, 160 participants

    PMID 20393946 · one of two readings recorded this

  • treatment response rate (at least 50% reduction on HAM-D or MADRS), remission, mean change in depression score, dropout and side effects, sertraline versus other antidepressants

    increases, OR 0.73, 95% CI 0.59 to 0.92 versus fluoxetine, p = 0.007

    Not recorded as a finding: the comparison was against another active treatment

    There was evidence that sertraline was more effective than fluoxetine (OR 0.73, 95% CI 0.59 to 0.92, p = 0.007; 8 studies, 1352 participants) (see Figure 10).

    PMID 20393946 · one of two readings recorded this

  • treatment response

    no effect, p = 0.07, n = 1345

    the difference between sertraline and amitriptyline was in favour of the latter (OR 1.23, 95% CI 0.99 to 1.52, p = 0.07; 7 studies, 1345 participants)

    PMID 20393946 · one of two readings recorded this

  • treatment response

    increases, p = 0.007, n = 1352

    There was evidence that sertraline was more effective than fluoxetine (OR 0.73, 95% CI 0.59 to 0.92, p = 0.007; 8 studies, 1352 participants)

    PMID 20393946 · one of two readings recorded this

  • treatment response

    decreases, p = 0.05, n = 596

    sertraline was less effective than mirtazapine (OR 1.40, 95% CI 1.00 to 1.94, p = 0.05; 2 studies, 596 participants)

    PMID 20393946 · one of two readings recorded this

  • tremor

    decreases, p = 0.03, n = 545

    tremor (OR 0.55, 95% CI 0.32 to 0.94, p = 0.03, 2 trials, 545 participants

    PMID 20393946 · one of two readings recorded this

  • urinary problems

    decreases, p = 0.02, n = 353

    urinary problems than paroxetine (OR 0.09, 95% CI 0.01 to 0.68, P = 0.02; 1 trial, 353 participants)

    PMID 20393946 · one of two readings recorded this

  • weight gain

    decreases, p = 0.00001, n = 596

    weight gain (OR 0.18, 95% CI 0.09 to 0.37, p<0.00001; 2 trials, 596 participants

    PMID 20393946 · one of two readings recorded this

  • correlation between maternal and infant serum desmethylsertraline concentration

    increases, Fisher's Z=0.391, 95% CI (0.071, 0.711), p = 0.017

    Maternal and infant desmethylsertraline levels were significantly correlated in these studies [Fisher's Z=0.391, p=0.017, 95% CI (0.071, 0.711)] and zero was not included in the confidence interval.

    PMID 25589155 · both readings recorded this

  • correlation between maternal and infant serum sertraline concentration in breastfeeding mother-infant dyads, Fisher's Z transformed Pearson correlation

    no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639

    Not recorded as a finding: this platform holds no node for the endpoint

    The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.

    PMID 25589155 · one of two readings recorded this

  • correlation between maternal and infant serum sertraline concentration in breastfeeding mother-infant dyads, meta-analytic Fisher's Z

    no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639

    Not recorded as a finding: this platform holds no node for the endpoint

    The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.

    PMID 25589155 · one of two readings recorded this

  • correlation between maternal and infant serum sertraline concentration

    no effect, Fisher's Z=0.048, 95% CI (-0.154, 0.251), p = 0.639

    The mean correlation depicting the relationship between maternal and infant sertraline concentrations in mother-baby dyads was small and not significant [Fisher's Z=0.048, p =0.639, 95% CI (−0.154, 0.251)] with confidence intervals including zero.

    PMID 25589155 · both readings recorded this

  • correlation between maternal and infant serum sertraline+desmethylsertraline sum concentration

    increases, Fisher's Z=0.367, 95% CI (0.080, 0.654), p = 0.012

    The sum of sertraline and desmethylsertraline was significantly correlated between mothers and infants in these studies [Fisher's Z=0.367, p=0.012, 95% CI (0.080, 0.654)] and zero was not included in the confidence interval.

    PMID 25589155 · one of two readings recorded this

  • Correlation between maternal and infant serum sum of sertraline plus desmethylsertraline concentration

    increases, Fisher's Z=0.367, 95% CI (0.080, 0.654), p = 0.012

    The sum of sertraline and desmethylsertraline was significantly correlated between mothers and infants in these studies [Fisher’s Z=0.367, p=0.012, 95% CI (0.080, 0.654)] and zero was not included in the confidence interval.

    PMID 25589155 · one of two readings recorded this

  • atrial and/or ventricular septal defects

    increases

    atrial and/or ventricular septal defects (OR = 1.36, 95% CI = 1.06-1.76; I2 = 62.2%; n = 8)

    PMID 27770542 · one of two readings recorded this

  • cardiovascular-related malformations

    increases

    infant cardiovascular-related malformations (OR = 1.36; 95% CI = 1.06-1.74; I2 = 64.4%; n = 12)

    PMID 27770542 · one of two readings recorded this

  • congenital anomalies of the digestive system

    no effect

    digestive system (OR = 1.23; 95% CI = 0.76-1.98; I2 = 0%; n = 5)

    PMID 27770542 · one of two readings recorded this

  • congenital anomalies of the eye, ear, face and neck

    no effect

    eye, ear, face and neck (OR = 1.08; 95% CI = 0.33-3.55; I2 = 32.1%; n = 3)

    PMID 27770542 · one of two readings recorded this

  • congenital anomalies of the musculoskeletal system

    no effect

    musculoskeletal system (OR = 0.97; 95% CI = 0.69-1.36; I2 = 0%; n = 5)

    PMID 27770542 · one of two readings recorded this

  • congenital anomalies of the nervous system

    no effect

    congenital anomalies of the nervous system (OR = 1.39; 95% CI = 0.83-2.32; I2 = 0%; n = 5)

    PMID 27770542 · one of two readings recorded this

  • congenital anomalies of the urogenital system

    no effect

    urogenital system (OR = 1.03; 95% CI = 0.73-1.46; I2 = 0%; n = 5)

    PMID 27770542 · one of two readings recorded this

  • adverse events

    no effect, RR 0.94; 95% CI 0.83-1.06, p = 0.33

    no significant difference between sertraline and control groups in the morbidity of adverse events (RR 0.94; 95% CI 0.83-1.06; P = .33 >0.05).

    PMID 30544429 · one of two readings recorded this

  • gastrointestinal upset (adverse event)

    increases, RR 2.71, 95% CI 1.39 to 5.28, p = 0.004

    Among them, a significant increased risk of gastrointestinal upset was observed in pooled results of 8 studies (RR 2.71, 95%CI 1.39 to 5.28, P =.004).

    PMID 31169738 · one of two readings recorded this

  • Gastrointestinal upset incidence (adverse event)

    increases, RR 2.71, 95% CI 1.39 to 5.28, p = 0.004

    Among them, a significant increased risk of gastrointestinal upset was observed in pooled results of 8 studies (RR 2.71, 95%CI 1.39 to 5.28, P =.004).

    PMID 31169738 · one of two readings recorded this

  • intravaginal ejaculation latency time (IELT), meta-analysed as standardised mean difference across trials of sertraline versus placebo/blank control

    increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830

    Not recorded as a finding: this platform holds no node for the endpoint

    Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).

    PMID 31169738 · one of two readings recorded this

  • intravaginal ejaculation latency time (IELT), patient-timed, meta-analytically pooled as SMD

    increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830

    Not recorded as a finding: this platform holds no node for the endpoint

    Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).

    PMID 31169738 · one of two readings recorded this

  • intravaginal ejaculation latency time (IELT)

    increases, SMD 2.14, 95% CI 1.20 to 3.08, n = 830

    Meta-analysis showed that sertraline can prolong the IELT (changes of IELT, SMD 2.14, 95% CI 1.20 to 3.08, P <.00001; I 2 = 96%).

    PMID 31169738 · both readings recorded this

  • patient sexual satisfaction rate

    increases, SMD 2.20, 95% CI 1.57 to 2.84

    Patients' sexual satisfaction rates were evaluated by 6, 7, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved patients' sexual satisfaction rates (SMD 2.20, 95%CI 1.57 to 2.84, P <.00001).

    PMID 31169738 · one of two readings recorded this

  • Patients' sexual satisfaction rate (IIEF items)

    increases, SMD 2.20, 95% CI 1.57 to 2.84

    Patients’ sexual satisfaction rates were evaluated by 6, 7, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved patients’ sexual satisfaction rates (SMD 2.20, 95%CI 1.57 to 2.84, P <.00001).

    PMID 31169738 · one of two readings recorded this

  • spouse sexual satisfaction rate

    increases, SMD 2.27, 95% CI 1.44 to 3.09

    Spouses' sexual satisfaction rates were evaluated by 6, 6, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved spouses' sexual satisfaction rates (SMD 2.27, 95%CI 1.44 to 3.09, P <.00001).

    PMID 31169738 · one of two readings recorded this

  • Spouses' sexual satisfaction rate (IIEF items)

    increases, SMD 2.27, 95% CI 1.44 to 3.09

    Spouses’ sexual satisfaction rates were evaluated by 6, 6, and 8 items in the IIEF (0–15 points) among 3 studies, and meta-analysis showed that sertraline improved spouses’ sexual satisfaction rates (SMD 2.27, 95%CI 1.44 to 3.09, P <.00001).

    PMID 31169738 · one of two readings recorded this

  • ANCOVA effect of group on baseline EFT interference (bupropion responders, non-responders, controls)

    unclear, p = 0.073

    F(2,64) = 2.73, p = 0.073, partial η2 = 0.079

    PMID 33213541 · one of two readings recorded this

  • ANCOVA effect of group on baseline response bias (bupropion responders, non-responders, controls)

    modulates, p = 0.002

    F(2,67) = 6.99, p = 0.002, partial η2 = 0.173

    PMID 33213541 · one of two readings recorded this

  • ANCOVA effect of group on baseline verbal fluency (bupropion responders, non-responders, controls)

    modulates, p = 0.003

    F(2,76) = 6.20, p = 0.003, partial η2 = 0.140

    PMID 33213541 · one of two readings recorded this

  • ANCOVA effect of group on early ABRT change (placebo responders, non-responders, controls)

    modulates, p = 0.039

    F(2,144) = 3.32, p = 0.039, partial η2 = 0.044

    PMID 33213541 · one of two readings recorded this

  • ANCOVA effect of group on early CRT change (placebo responders, non-responders, controls)

    modulates, p = 0.008

    F(2,157) = 4.94, p = 0.008, partial η2 = 0.059

    PMID 33213541 · one of two readings recorded this

  • baseline EFT interference, bupropion responders vs non-responders (post-hoc)

    unclear, p = 0.089

    t(35) = 2.22, p = 0.089, Cohen’s d = 0.74

    PMID 33213541 · one of two readings recorded this

  • baseline EFT interference, controls vs bupropion non-responders (post-hoc)

    no effect, p = 0.71

    t(58) = 0.38, p = 0.71, Cohen’s d = 0.10

    PMID 33213541 · one of two readings recorded this

  • baseline EFT interference, controls vs bupropion responders (post-hoc)

    no effect, p = 0.134

    t(50) = −2.05, p = 0.134, Cohen’s d = 0.65

    PMID 33213541 · one of two readings recorded this

  • baseline response bias, bupropion non-responders vs controls (post-hoc)

    decreases, p = 0.005

    t(59) = 3.27, p = 0.005, Cohen’s d = 0.86

    PMID 33213541 · one of two readings recorded this

  • baseline response bias, bupropion non-responders vs responders (post-hoc)

    decreases, p = 0.006

    t(37) = 3.22, p = 0.006, Cohen’s d = 1.00

    PMID 33213541 · one of two readings recorded this

  • baseline response bias, bupropion responders vs controls (post-hoc)

    no effect, p = 0.56

    t(53) = 0.585, p = 0.56, Cohen’s d = 0.16

    PMID 33213541 · one of two readings recorded this

  • baseline verbal fluency, bupropion non-responders vs controls (post-hoc)

    decreases, p = 0.003

    t(64) = −3.45, p = 0.003, Cohen’s d = 0.88

    PMID 33213541 · one of two readings recorded this

  • baseline verbal fluency, bupropion non-responders vs responders (post-hoc)

    decreases, p = 0.074

    t(41) = −2.29, p = 0.074, Cohen’s d = 0.71

    PMID 33213541 · one of two readings recorded this

  • baseline verbal fluency, bupropion responders vs controls (post-hoc)

    no effect, p = 0.62

    t(56) = 0.505, p = 0.62, Cohen’s d = 0.15

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by baseline ABRT, sertraline vs placebo

    unclear, p = 0.088

    B = −0.52, 95% CI = −1.13 to 0.07, p = 0.088

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by baseline ABRT, simpler model

    no effect, p = 0.553

    B = −0.14, 95% CI = −0.60 to 0.32, p = 0.553

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by baseline CRT, placebo vs sertraline

    modulates, p = 0.01

    B = −0.69, 95% CI = −1.23 to −0.18, p = 0.010

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by baseline CRT, simpler model

    no effect, p = 0.27

    B = −0.25, 95% CI = −0.69 to 0.19, p = 0.270

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by baseline EFT interference, bupropion vs sertraline

    modulates, p = 0.007

    B = 0.081, 95% CI = 0.027–0.15, p = 0.007

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by baseline response bias, bupropion vs sertraline

    modulates, p = 0.003

    B = 11.8, 95% CI = 4.60–20.6, p = 0.003

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by baseline verbal fluency, bupropion vs sertraline

    modulates, p = 0.035

    B = 1.01, 95% CI = 0.097–2.00, p = 0.035

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by early ABRT change, placebo vs sertraline

    modulates, p = 0.027

    B = 1.11, 95% CI = 0.16–2.12, p = 0.027

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by early ABRT change, simpler model

    unclear, p = 0.052

    B = 0.74, 95% CI = 0.018–1.52, p = 0.052

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by early CRT change, placebo vs sertraline

    modulates, p = 0.001

    B = 1.71, 95% CI = 0.71–2.79, p = 0.001

    PMID 33213541 · one of two readings recorded this

  • difference in response prediction by early CRT change, simpler model

    modulates, p = 0.018

    B = 1.03, 95% CI = 0.19–1.91, p = 0.018

    PMID 33213541 · one of two readings recorded this

  • early ABRT change, controls vs placebo non-responders (post-hoc)

    no effect, p = 0.76

    t(106) = 0.30, p = 0.76, Cohen’s d = 0.06

    PMID 33213541 · one of two readings recorded this

  • early ABRT change, controls vs placebo responders (post-hoc)

    no effect, p = 0.168

    t(80) = 1.93, p = 0.168, Cohen’s d = 0.42

    PMID 33213541 · one of two readings recorded this

  • early ABRT change, placebo responders vs non-responders (post-hoc)

    increases, p = 0.043

    t(113) = 2.49, p = 0.043, Cohen’s d = 0.48

    PMID 33213541 · one of two readings recorded this

  • early CRT change, placebo non-responders vs controls (post-hoc)

    decreases, p = 0.055

    t(117) = −2.38, p = 0.055, Cohen’s d = 0.46

    PMID 33213541 · one of two readings recorded this

  • early CRT change, placebo non-responders vs responders (post-hoc)

    decreases, p = 0.019

    t(124) = −2.77, p = 0.019, Cohen’s d =0.51

    PMID 33213541 · one of two readings recorded this

  • early CRT change, placebo responders vs controls (post-hoc)

    no effect, p = 0.79

    t(84) = 0.272, p = 0.79, Cohen’s d = 0.05

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline ABRT (placebo)

    decreases, p = 0.025

    B = −0.52, 95% CI = −0.97 to -0.07, p = 0.025

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline ABRT (sertraline)

    no effect, p = 0.994

    B = −0.002, 95% CI = −0.41 to 0.41, p = 0.994

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline CRT (placebo)

    decreases, p = 0.011

    B = −0.55, 95% CI = −0.97 to -0.13, p = 0.011

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline CRT (sertraline)

    no effect, p = 0.392

    B = 0.14, 95% CI = −0.18 to 0.47, p = 0.392

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline EFT interference (bupropion)

    increases, p = 0.01

    B = 0.065, 95% CI = 0.016–0.11, p = 0.010

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline EFT interference (sertraline)

    no effect, p = 0.321

    B = −0.016, 95% CI = −0.049 to 0.015, p = 0.321

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline response bias, PRT (bupropion after sertraline)

    increases, p = 0.008

    B = 9.59, 95% CI = 2.46–16.3, p = 0.008

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline response bias, PRT (sertraline after placebo)

    no effect, p = 0.249

    B = −2.20, 95% CI = −6.27 to 1.35, p = 0.249

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline verbal fluency (bupropion)

    unclear, p = 0.067

    B = 0.66, 95% CI = −0.046 to 1.37, p = 0.067

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs baseline verbal fluency (sertraline)

    no effect, p = 0.259

    B = −0.34, 95% CI = −0.97 to 0.24, p = 0.259

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs early ABRT change (placebo)

    increases, p = 0.015

    B = 0.81, 95% CI = 0.16–1.47, p = 0.015

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs early ABRT change (sertraline)

    no effect, p = 0.429

    B = −0.29, 95% CI = −1.05 to 0.43, p = 0.429

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs early CRT change (placebo)

    increases, p = 0.012

    B = 1.05, 95% confidence interval (CI) = 0.23–1.86, p = 0.012

    PMID 33213541 · one of two readings recorded this

  • response likelihood vs early CRT change (sertraline)

    decreases, p = 0.037

    B = −0.67, 95% CI = −1.32 to -0.06, p = 0.037

    PMID 33213541 · one of two readings recorded this

  • hits: three-way interaction treatment x valence x baseline CIS-R depressive symptoms, fully adjusted

    unclear, p = 0.06

    adjusted interaction hits ratio = 1.02, 95% CI 1.00–1.05, p = 0.06

    PMID 33431087 · one of two readings recorded this

  • hits: three-way interaction treatment x valence x baseline GAD-7, fully adjusted

    no effect, p = 0.47

    adjusted interaction hits ratio = 1.01, 95% CI 0.99–1.03, p = 0.47

    PMID 33431087 · one of two readings recorded this

  • negative false alarms, 2 weeks

    no effect

    2 weeks | 281 | 0.88 (1.14) | 272 | 0.94 (1.13)

    PMID 33431087 · one of two readings recorded this

  • negative false alarms, 6 weeks

    no effect

    6 weeks | 276 | 0.94 (1.27) | 260 | 1.10 (1.37)

    PMID 33431087 · one of two readings recorded this

  • negative false alarms, baseline

    Baseline | 291 | 0.87 (1.16) | 284 | 0.91 (1.27)

    PMID 33431087 · one of two readings recorded this

  • negative hits, 2 weeks

    no effect

    2 weeks | 281 | 2.09 (1.45) | 272 | 2.07 (1.49)

    PMID 33431087 · one of two readings recorded this

  • negative hits, 6 weeks

    no effect

    6 weeks | 275 | 2.04 (1.70) | 259 | 2.00 (1.62)

    PMID 33431087 · one of two readings recorded this

  • negative hits, baseline (word recall)

    Baseline | 291 | 1.93 (1.38) | 284 | 2.07 (1.50)

    PMID 33431087 · one of two readings recorded this

  • negative hits: interaction treatment x time (2 vs 6 weeks), fully adjusted

    no effect, p = 0.95

    adjusted interaction hits ratio = 1.01, 95% CI 0.85–1.19, p = 0.95

    PMID 33431087 · one of two readings recorded this

  • negative hits ratio, fully adjusted (2 and 6 weeks)

    no effect, p = 0.85, n = 574

    Fully adjusted b | 574 | 0.98 (0.90–1.06) | 0.56 | 574 | 0.99 (0.91–1.08) | 0.85

    PMID 33431087 · one of two readings recorded this

  • negative hits ratio, partially adjusted (2 and 6 weeks)

    no effect, p = 0.85, n = 574

    Partially adjusted a | 574 | 0.99 (0.91–1.07) | 0.73 | 574 | 0.99 (0.91–1.08) | 0.85

    PMID 33431087 · one of two readings recorded this

  • negative hits ratio, sertraline vs placebo

    no effect

    High depressive symptoms | 2.12 (1.37) | 2.16 (1.42) | 2.06 (1.56) | 1.95 (1.50) | 2.10 (1.30) | 2.04 (1.51) | 1.07 (0.93–1.23)

    PMID 33431087 · one of two readings recorded this

  • negative hits ratio, sertraline vs placebo

    no effect

    Low depressive symptoms | 1.86 (1.43) | 1.99 (1.50) | 2.15 (1.91) | 2.10 (1.46) | 1.86 (1.74) | 1.85 (1.47) | 0.92 (0.77–1.10)

    PMID 33431087 · one of two readings recorded this

  • negative hits ratio, sertraline vs placebo

    no effect

    Moderate depressive symptoms | 1.74 (1.31) | 2.09 (1.43) | 1.91 (1.66) | 2.19 (1.55) | 2.27 (1.36) | 2.13 (1.89) | 0.95 (0.80–1.12)

    PMID 33431087 · one of two readings recorded this

  • negative hits ratio, unadjusted (2 and 6 weeks)

    no effect, p = 0.81, n = 576

    Unadjusted | 576 | 0.98 (0.89–1.08) | 0.66 | 576 | 0.99 (0.89–1.10) | 0.81

    PMID 33431087 · one of two readings recorded this

  • number of positive and negative personality words correctly recalled (hits) after the emotional categorisation task (ECAT) free recall, at 2 and 6 weeks, sertraline vs placebo, Poisson mixed models

    no effect, adjusted positive hits ratio 0.98, 95% CI 0.90-1.06, p = 0.56

    Not recorded as a finding: this platform holds no node for the endpoint

    We found no evidence that treatment allocation was associated with positive hits (adjusted hits ratio = 0.98, 95% CI 0.90–1.06, p = 0.56; Table 3).

    PMID 33431087 · one of two readings recorded this

  • number of positive and negative personality words correctly recalled (hits) on an incidental recall task after the emotional categorisation task, Poisson mixed models, sertraline vs placebo at 2 and 6 weeks

    no effect, adjusted hits ratio 0.98, 95% CI 0.90-1.06 for positive hits, p = 0.56

    Not recorded as a finding: this platform holds no node for the endpoint

    We found no evidence that treatment allocation was associated with positive hits (adjusted hits ratio = 0.98, 95% CI 0.90–1.06, p = 0.56; Table 3).

    PMID 33431087 · one of two readings recorded this

  • positive false alarms, 2 weeks

    no effect

    2 weeks | 281 | 1.60 (1.61) | 272 | 1.55 (1.45)

    PMID 33431087 · one of two readings recorded this

  • positive false alarms, 6 weeks

    no effect

    6 weeks | 276 | 1.30 (1.49) | 260 | 1.55 (1.67)

    PMID 33431087 · one of two readings recorded this

  • positive false alarms, baseline

    Baseline | 291 | 1.29 (1.42) | 284 | 1.33 (1.37)

    PMID 33431087 · one of two readings recorded this

  • positive hits, 2 weeks

    no effect

    2 weeks | 281 | 3.11 (2.00) | 272 | 2.95 (1.98)

    PMID 33431087 · one of two readings recorded this

  • positive hits, 6 weeks

    no effect

    6 weeks | 276 | 2.31 (1.62) | 260 | 2.32 (1.60)

    PMID 33431087 · one of two readings recorded this

  • positive hits, baseline (word recall)

    Baseline | 291 | 3.03 (1.73) | 284 | 2.88 (1.77)

    PMID 33431087 · one of two readings recorded this

  • positive hits: interaction treatment x time (2 vs 6 weeks), fully adjusted

    no effect, p = 0.18

    adjusted interaction hits ratio = 1.11, 95% CI 0.96–1.28, p = 0.18

    PMID 33431087 · one of two readings recorded this

  • positive hits ratio, fully adjusted (2 and 6 weeks)

    no effect, p = 0.56, n = 574

    Fully adjusted b | 574 | 0.98 (0.90–1.06) | 0.56 | 574 | 0.99 (0.91–1.08) | 0.85

    PMID 33431087 · one of two readings recorded this

  • positive hits ratio, partially adjusted (2 and 6 weeks)

    no effect, p = 0.73, n = 574

    Partially adjusted a | 574 | 0.99 (0.91–1.07) | 0.73 | 574 | 0.99 (0.91–1.08) | 0.85

    PMID 33431087 · one of two readings recorded this

  • positive hits ratio, sertraline vs placebo

    no effect

    High depressive symptoms | 3.12 (1.74) | 3.29 (2.00) | 2.40 (1.66) | 2.67 (1.57) | 2.86 (1.94) | 2.31 (1.63) | 1.00 (0.88–1.13)

    PMID 33431087 · one of two readings recorded this

  • positive hits ratio, sertraline vs placebo

    no effect

    Low depressive symptoms | 3.12 (1.77) | 3.18 (2.10) | 2.45 (1.69) | 3.02 (1.97) | 2.87 (2.05) | 2.26 (1.48) | 0.92 (0.79–1.06)

    PMID 33431087 · one of two readings recorded this

  • positive hits ratio, sertraline vs placebo

    no effect

    Moderate depressive symptoms | 2.80 (1.65) | 2.78 (1.86) | 2.01 (1.45) | 3.00 (1.76) | 3.19 (1.94) | 2.43 (1.70) | 1.05 (0.90–1.23)

    PMID 33431087 · one of two readings recorded this

  • positive hits ratio, unadjusted (2 and 6 weeks)

    no effect, p = 0.66, n = 576

    Unadjusted | 576 | 0.98 (0.89–1.08) | 0.66 | 576 | 0.99 (0.89–1.10) | 0.81

    PMID 33431087 · one of two readings recorded this

  • total hits: interaction treatment x time, fully adjusted

    no effect, p = 0.25

    adjusted interaction between treatment allocation and time hits ratio = 1.07, 95% CI 0.96–1.19, p = 0.25

    PMID 33431087 · one of two readings recorded this

  • total hits: interaction treatment x valence (Model 2), fully adjusted

    no effect, p = 0.87, n = 574

    Fully adjusted b | 574 | 0.98 (0.92–1.05) | 0.61 | 1.01 (0.90–1.13) | 0.87

    PMID 33431087 · one of two readings recorded this

  • total hits: interaction treatment x valence (Model 2), partially adjusted

    no effect, p = 0.87, n = 574

    Partially adjusted a | 574 | 0.99 (0.93–1.06) | 0.75 | 1.01 (0.90–1.13) | 0.87

    PMID 33431087 · one of two readings recorded this

  • total hits: interaction treatment x valence (Model 2), unadjusted

    no effect, p = 0.82, n = 576

    Unadjusted | 576 | 0.99 (0.90–1.08) | 0.74 | 1.01 (0.91–1.13) | 0.82

    PMID 33431087 · one of two readings recorded this

  • total hits: three-way interaction treatment x valence x time, fully adjusted

    no effect, p = 0.51

    adjusted interaction between treatment allocation, valence and time hits ratio = 0.93, 95% CI 0.74–1.15, p = 0.51

    PMID 33431087 · one of two readings recorded this

  • total hits: treatment effect (Model 1), fully adjusted

    no effect, p = 0.61, n = 574

    Fully adjusted b | 574 | 0.98 (0.92–1.05) | 0.61 | 1.01 (0.90–1.13) | 0.87

    PMID 33431087 · one of two readings recorded this

  • total hits: treatment effect (Model 1), partially adjusted

    no effect, p = 0.75, n = 574

    Partially adjusted a | 574 | 0.99 (0.93–1.06) | 0.75 | 1.01 (0.90–1.13) | 0.87

    PMID 33431087 · one of two readings recorded this

  • total hits: treatment effect (Model 1), unadjusted

    no effect, p = 0.74, n = 576

    Unadjusted | 576 | 0.99 (0.90–1.08) | 0.74 | 1.01 (0.91–1.13) | 0.82

    PMID 33431087 · one of two readings recorded this

  • CGI-I minimally improved, post-treatment

    Minimally improved | 16.3 | 18.2 | 13 | 17.5

    PMID 34463234 · one of two readings recorded this

  • CGI-I much improved, post-treatment and follow-up

    Much improved | 32.7 | 40 | 17.4 | 27.5

    PMID 34463234 · one of two readings recorded this

  • CGI-I no change, post-treatment

    No change | 6.1 | 4.5 | 2.2 | 5

    PMID 34463234 · one of two readings recorded this

  • CGI-I very much improved, follow-up

    no effect, p = 0.73, n = 85

    Very much improved | 44.9 | 36.4 | χ2(3, N = 94) = 0.999, p = 0.80 | 67.4 | 50 | χ2(3, N = 85) = 0.12, p = 0.73

    PMID 34463234 · one of two readings recorded this

  • CGI-I very much improved, post-treatment

    no effect, p = 0.8, n = 94

    Very much improved | 44.9 | 36.4 | χ2(3, N = 94) = 0.999, p = 0.80 | 67.4 | 50 | χ2(3, N = 85) = 0.12, p = 0.73

    PMID 34463234 · one of two readings recorded this

  • emotional outbursts (SSRI side effects checklist, weekly)

    decreases, p = 0.031, n = 97

    emotional outbursts, χ2(1, N = 97) = 4.67, p = 0.031

    PMID 34463234 · one of two readings recorded this

  • irritability symptoms (SSRI side effects checklist, weekly)

    decreases, p = 0.026, n = 97

    Children in the CBT + PBO condition reported significantly greater mean irritability symptoms, χ2(1, N = 97) = 4.98, p = 0.026

    PMID 34463234 · one of two readings recorded this

  • medication adherence (pill counts and diaries)

    children and families showed excellent adherence to the medication treatment protocol (CBT + SERT: 92.4%; CBT + PBO: 95.67%)

    PMID 34463234 · one of two readings recorded this

  • remission of all anxiety diagnoses, follow-up

    no effect, p = 0.73, n = 85

    Anxiety diagnoses | 61.2 | 51.1 | χ2(1, N = 94) = 0.98, p = 0.32, Cohen's d = 0.21 | 65.2 | 61.5 | χ2(1, N = 85) = 0.12, p = 0.73, Cohen's d = 0.08

    PMID 34463234 · one of two readings recorded this

  • remission of all anxiety diagnoses, post-treatment

    no effect, p = 0.32, n = 94

    Anxiety diagnoses | 61.2 | 51.1 | χ2(1, N = 94) = 0.98, p = 0.32, Cohen's d = 0.21 | 65.2 | 61.5 | χ2(1, N = 85) = 0.12, p = 0.73, Cohen's d = 0.08

    PMID 34463234 · one of two readings recorded this

  • remission of primary anxiety disorder and of all anxiety diagnoses (clinical severity rating below 4 on a modified ADIS-IV-C/P) at post-treatment and 6-month follow-up, CBT plus sertraline vs CBT plus placebo in youth

    no effect, no significant difference in remission rates between CBT + SERT and CBT + PBO

    Not recorded as a finding: this platform holds no node for the endpoint

    At post and follow-up, there were no significant differences across conditions in remission rates based on primary disorder or all anxiety disorders (see Table 3 and Fig. 2).

    PMID 34463234 · one of two readings recorded this

  • remission of primary anxiety disorder and of all anxiety disorders (clinical severity rating below 4 on ADIS-IV-C/P) at post-treatment and 6 months; SCAS child and parent anxiety symptoms; SMFQ depressive symptoms; CALIS life interference

    no effect, no significant differences across conditions in remission rates, CBT plus sertraline vs CBT plus placebo

    Not recorded as a finding: this platform holds no node for the endpoint

    At post and follow-up, there were no significant differences across conditions in remission rates based on primary disorder or all anxiety disorders (see Table 3 and Fig. 2).

    PMID 34463234 · one of two readings recorded this

  • remission of primary anxiety disorder, follow-up

    no effect, p = 0.63, n = 85

    Primary | 71.4 | 68.9 | χ2(1, N = 94) = 0.07, p = 0.79, Cohen's d = 0.05 | 73.9 | 69.2 | χ2(1, N = 85) = 0.23, p = 0.63, Cohen's d = 0.10

    PMID 34463234 · one of two readings recorded this

The whole record — 924 rows